Table 2 : Evaluation of SNPs significantly associated with non-small cell lung cancer with the
False Discovery Reporting Percentage Method.


Race Gene Refseq OR*** (95% CI) 0.1 A Prior FPRP (OR 2.0) 0.25 A Prior FPRP (OR 2.0)

Whites: APAF-1 rs1007573 1.86 (1.17-2.95) 0.108* 0.0399**
CD40 rs3765459 0.62 (0.42-0.90) 0.105* 0.038**
CD40 rs1535045 0.58 (0.40-0.84) 0.045* 0.016**

African Americans: ATM rs1801516 24.15 (3.50-166.55 0.659 0.392
BAK1 rs513349 0.35 (0.12-0.98) 0.629 0.361
TNF rs1800629 0.42 (0.18-0.99) 0.548 0.288
P63 rs6790167 2.85 (1.33-6.09) 0.254 0.102**
P63 rs7613791 2.70 (1.26-5.82) 0.31 0.13**
P63 rs35592567 0.44 (0.20-0.95) 0.471 0.235
P63 rs3856775 2.13 (1.03-4.43) 0.467 0.226

*Significant with an a priori hypothesis that the SNP may be associated with lung cancer.
**Significant with an a priori hypothesis that the SNP has a high likelihood of being associated with
lung cancer.
***Adjusted for age, pack years smoked, ever/never smoking status, family history of lung cancer,
history of COPD, BMI and education.

Pathak et al.Journal of Cancer Therapeutics and Research  2014 3:1DOI : 10.7243/2049-7962-3-1